Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2026 January
  • Home
  • Archive for January, 2026
Watsnex Podcast
user

Host: Pascal Côté linkedin-img

user

Guest: Ross Youngs linkedin-img


×

AI, Microbiomes, & 8 Orders of Magnitude Improvement

  • January 29 2026
  • Video - Date: 01/26/2026
  • Length: 25:34 min

AI, Microbiomes, & 8 Orders of Magnitude Improvement

Summary – I recently sat down with Pascal Côté on the WATSNEX Podcast to discuss “AI, Microbiomes, and 8 Orders of Magnitude Improvement.” We dove deep into how industrial-scale microbiome mining and data depth are transforming biotech manufacturing and drug discovery. This conversation is part of the WATSNEX Podcast Founding Series, featuring leaders in biopharma and medtech. Watch the full episode here: https://youtu.be/16dg9QKOEcM

Reel1: https://youtube.com/shorts/tHsW1XkqEuw?feature=share

Reel2: https://youtube.com/shorts/AQhGTWx94EU?feature=share

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

  • January 27 2026

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

Continue Reading

RSS Industry News

  • Sialic acid exacerbates polycystic ovary syndrome in mice by modulating gut microbiota-mediated bile acid metabolism and FXR activation March 31 2026
  • Early life bacteria and sibling exposure associate with restoration of the infant gut microbiome after cesarean section March 30 2026
  • Multi-omics reveals the involvement of endophytes in the growth of Moso bamboo (Phyllostachys edulis) shoots March 26 2026
  • Atlas of one-carbon metabolism in conventional and germ-free mice reveals folate as a key determinant of biochemical pathways March 26 2026
  • Cats on dry kibble diet have significantly different microbiome than those on canned wet food March 26 2026
  • Modulating microbial intake helps to maintain the gut microbiome diversity March 26 2026
  • Pseudomonas plecoglossicida disrupts intestinal homeostasis through manipulation of palmitoleic acid microbial metabolism March 24 2026
  • Diet–microbiome associations in 10,068 individuals from the Human Phenotype Project to guide personalized nutrition March 23 2026
  • Metagenomic and functional insights into root endophytic bacteria associated with drought stress in cowpea March 22 2026
  • Taxonomic composition and ecophysiology of resident bacteria associated with marine phytoplankton March 20 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Drug developer Generate Biomedicines raises $400 million in US IPO
  • Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
  • AI, Microbiomes, & 8 Orders of Magnitude Improvement
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.